Zepubresib Hydrochloride Drug Due Diligence Report 2026

This Zepubresib Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Zepubresib Hydrochloride can convert its Small molecule drug profile and BRD4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zepubresib Hydrochloride (query alias: Zepubresib Hydrochloride)
Modality / target	Small molecule drug; BRD4; BRD4 inhibitors, Epigenetic drug
Highest global status	Phase 2
Originator	Ningbo Wenda Pharmaceutical Technology Co., Ltd
Active developers	Ningbo Wenda Pharmaceutical Technology Co., Ltd

The MCP disease footprint includes NUT midline carcinoma, Primary cutaneous diffuse large cell B-cell lymphoma, Diffuse large B-cell lymphoma refractory. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20262196	Phase 1	Recruiting	6	Primary endpoint not disclosed in English source
NCT06527300	Phase 2	Unknown status	48	Primary endpoint not disclosed in English source
NCT06073938	Not Applicable	Recruiting	30	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zepubresib Hydrochloride addresses NUT midline carcinoma, Primary cutaneous diffuse large cell B-cell lymphoma, Diffuse large B-cell lymphoma refractory. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 11 matched transaction record(s) under the scope “target-level comparable: BRD4.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: BRD4 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-11-17	J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash	Phase 1/2	US$3,000.0M stated total
2022-11-21	Opna Bio has acquired a diverse portfolio of clinical and preclinical oncology programs from Plexxikon Inc	Phase 1/2	Financial terms not disclosed
2021-08-03	Sierra Oncology collaborates with Astrazeneca to globally develop and commercialize AZD-5153 and its related compounds for myelofibrosis.	Phase 1/2	US$216.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Patent source description not available in English”. The milestone feed surfaced a patent-application signal described as “Carboline derivative serving as bromodomain inhibitor”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION